A study aimed to identify differences between psoriasis patients who fail multiple biologic therapies and those who respond to their first biologic. The study analyzed data from 1,039 patients and discovered that certain factors, such as being female, having hyperlipidemia, and being a Medicaid enrollee, were associated with multiple biologic therapy failures. These findings suggest that such patients might benefit from more frequent follow-ups.

The study’s results indicate that certain comorbidities, like hyperlipidemia, could be markers of psoriasis that is more difficult to treat. While further research is necessary, Dr. Wilson Liao, who led the study, suggests that dermatologists should consider closer monitoring of patients with these characteristics before initiating biologic treatment for psoriasis. The findings are significant for the psoriatic disease community and point toward more targeted approaches in treating and managing psoriasis. Additional research projects in this area are underway with the National Psoriasis Foundation and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis.

Reference: Harris S. Why Do Multiple Biologics Fail Some Patients With Psoriasis? MedPage Today. Updated February 23, 2024. Accessed March 29, 2024. https://www.medpagetoday.com/reading-room/aad/psoriasis/108865